Payment overview · 2025
General Payments
$247.12
2 reported records · 2 companies
Healthcare provider profile · identity verified
L. Lee Nelson, MD
Allopathic & Osteopathic Physicians|Emergency Medicine · NORWALK, CA · NPI 1407972656
Verified facts
What the public records show
CMS Open Payments records show L. Lee Nelson, MD received $247.12 in general payments during 2025 across 2 reported records.
Napo Pharmaceuticals Inc accounted for 51.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 2 associated products.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Napo Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $127.81 | 51.7% | 1 | 2025 |
| Braeburn Inc. | Unresolved — no canonical attribution shown | $119.31 | 48.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $247.12 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Mytesi Normalized: mytesi |
Drug | Napo Pharmaceuticals Inc | $127.81 | 1 | 2025 |
Source payment records
|
|||||
| BRIXADI Normalized: brixadi |
Drug | Braeburn Inc. | $119.31 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
No publishable same-company prescribing overlap was found in the loaded Part D year. This does not mean the doctor never prescribed a drug reported elsewhere by a paying company.
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 315 | 114 |
| Metformin Hcl | Metformin Hcl | 259 | 90 |
| Amlodipine Besylate | Amlodipine Besylate | 238 | 81 |
| Omeprazole | Omeprazole | 164 | 60 |
| Gabapentin | Gabapentin | 147 | 51 |
| Furosemide | Furosemide | 139 | 45 |
| Losartan Potassium | Losartan Potassium | 127 | 48 |
| Tamsulosin Hcl | Tamsulosin Hcl | 107 | 43 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 102 | 53 |
| Levothyroxine Sodium | Levothyroxine Sodium | 102 | 34 |
| Famotidine | Famotidine | 101 | 34 |
| Metoprolol Succinate | Metoprolol Succinate | 99 | 33 |
| Lisinopril | Lisinopril | 90 | 31 |
| Prednisone | Prednisone | 85 | 80 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 81 | 25 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 69 | 25 |
| Hydrochlorothiazide | Hydrochlorothiazide | 69 | 29 |
| Januvia | Sitagliptin Phosphate | 67 | 13 |
| Simvastatin | Simvastatin | 67 | 20 |
| Potassium Chloride | Potassium Chloride | 66 | 18 |
| Azithromycin | Azithromycin | 65 | 63 |
| Jardiance | Empagliflozin | 63 | 21 |
| Carvedilol | Carvedilol | 58 | 17 |
| Alendronate Sodium | Alendronate Sodium | 53 | 15 |
| Benazepril Hcl | Benazepril Hcl | 53 | 18 |
| Ibuprofen | Ibuprofen | 52 | 46 |
| Cephalexin | Cephalexin | 49 | 47 |
| Pantoprazole Sodium | Pantoprazole Sodium | 47 | 26 |
| Glimepiride | Glimepiride | 46 | 14 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 46 | 17 |
| Eliquis | Apixaban | 43 | 17 |
| Clopidogrel | Clopidogrel Bisulfate | 42 | 16 |
| Duloxetine Hcl | Duloxetine Hcl | 41 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 39 | 13 |
| Nitroglycerin | Nitroglycerin | 38 | 12 |
| Clonidine Hcl | Clonidine Hcl | 36 | 13 |
| Diclofenac Sodium | Diclofenac Sodium | 36 | 14 |
| Fluticasone Propionate | Fluticasone Propionate | 34 | 14 |
| Finasteride | Finasteride | 33 | 11 |
| Metoprolol Tartrate | Metoprolol Tartrate | 33 | 13 |
| Hydralazine Hcl | Hydralazine Hcl | 32 | 12 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 32 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 32 | 11 |
| Tramadol Hcl | Tramadol Hcl | 32 | 32 |
| Escitalopram Oxalate | Escitalopram Oxalate | 30 | 17 |
| Vascepa | Icosapent Ethyl | 29 | suppressed |
| Atenolol | Atenolol | 27 | suppressed |
| Latanoprost | Latanoprost | 27 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 27 | 11 |
| Glipizide | Glipizide | 25 | 12 |
| Ondansetron Hcl | Ondansetron Hcl | 25 | 25 |
| Pioglitazone Hcl | Pioglitazone Hcl | 25 | suppressed |
| Allopurinol | Allopurinol | 23 | suppressed |
| Colchicine | Colchicine | 23 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 23 | suppressed |
| Ozempic | Semaglutide | 22 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 21 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 21 | suppressed |
| Ketoconazole | Ketoconazole | 21 | suppressed |
| Myrbetriq | Mirabegron | 20 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 20 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 20 | 11 |
| Alcohol Swabs | Alcohol Antiseptic Pads | 19 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 19 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 18 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 18 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 18 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 18 | suppressed |
| Nifedipine Er | Nifedipine | 18 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 17 | 17 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 17 | 12 |
| Cyclosporine | Cyclosporine | 17 | suppressed |
| Meloxicam | Meloxicam | 17 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 17 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 17 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 16 | suppressed |
| Loperamide | Loperamide Hcl | 16 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 16 | suppressed |
| Lovastatin | Lovastatin | 16 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 16 | 16 |
| Xarelto | Rivaroxaban | 16 | suppressed |
| Clotrimazole | Clotrimazole | 15 | suppressed |
| Naproxen | Naproxen | 15 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 15 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 15 | suppressed |
| Spironolactone | Spironolactone | 15 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 15 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 15 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 14 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 14 | suppressed |
| Baclofen | Baclofen | 13 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 13 | 12 |
| Dicyclomine Hcl | Dicyclomine Hcl | 13 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 13 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 13 | suppressed |
| Entresto | Sacubitril/Valsartan | 13 | suppressed |
| Lorazepam | Lorazepam | 13 | 12 |
| Lumigan | Bimatoprost | 13 | suppressed |
| Synjardy | Empagliflozin/Metformin Hcl | 13 | suppressed |
| Topiramate | Topiramate | 13 | suppressed |
| Atrovent Hfa | Ipratropium Bromide | 12 | suppressed |
| Celecoxib | Celecoxib | 12 | suppressed |
| Creon | Lipase/Protease/Amylase | 12 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 12 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 12 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 12 | suppressed |
| Linzess | Linaclotide | 12 | suppressed |
| Restasis | Cyclosporine | 12 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 12 | suppressed |
| Timolol Maleate | Timolol Maleate | 12 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Aripiprazole | Aripiprazole | 11 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Ezetimibe | Ezetimibe | 11 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 11 | suppressed |
| Methimazole | Methimazole | 11 | suppressed |
| Mirtazapine | Mirtazapine | 11 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 11 | suppressed |
| Valsartan | Valsartan | 11 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $247.12 · 2 records | Napo Pharmaceuticals Inc | BRIXADI, Mytesi | — | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error